Anti-Mgll antibody
Description
Application Data
Description
-
An antibody against monoglyceride lipase (MGLL) in rat. A target for clinical intervention for the treatment of neurological disorders.
Application Data
-
Data Sheet Material Safety Data Sheet (MSDS)Catalogue number crb2005779 Antibody Anti-Mgll antibody Antigen Peptide KLH conjugated synthetic peptide crb1200988 Protein ID UniProtKB - O35678 (Mouse), Q8R431 (Rat) Aliases Monoglyceride lipase, Monoacylglycerol lipase Cross-Reactivity Rat, Mouse Host Species Rabbit Antibody Type Polyclonal Concentration 1.0 mg/ml Glycine Target Monoglyceride lipase Storage This material is supplied in PBS containing 0.01% sodium azide and 1% trehalose. The product should be stored at +4°C for short term storage and -20°C for long term storage. Avoid repeated freeze/thaw cycles. References Cisar et al., (2018). Identification of ABX-1431, a Selective Inhibitor of Monoacylglycerol Lipase and Clinical Candidate for Treatment of Neurological Disorders. J. Med. Chem., 61(20): 9062. doi: 10.1021/acs.jmedchem.8b00951.
Clapper et al., (2018). Pharmacological Characterization of MGLL Inhibitor ABD-1970. J. Pharmacol. Exp., 367(3): 494. doi: 10.1124/jpet.118.252296.
Monoglyceride lipase (MGLL) is a serine hydrolase enzyme that regulates the endocannabinoid and eicosanoid families of lipid signalling molecules. MGLL is the primary degradative enzyme for the endocannabinoid 2-arachidonoylglycerol(2-AG), an endogenous ligand of the cannabinoid receptors 1 and 2 (CB1 and CB2). MGLL is colocalized with CB1 in presynaptic neurons MGLL to tightly control 2-Ag signal termination.
MGLL hydrolyses the endocannabinoid 2-AG, thereby regulating endocannabinoid signalling, nociperception and perception of pain. Short-term MGLL inhibition causes analgesia, and anti-epileptogenic effects. Long-term inhibition causes tolerance to endocannabinoids acting on brain cannabinoid receptor CNR1 and a reduction in brain cannabinoid receptor CNR1 activity. MGLL inhibitors are being explored for the ability to activate the beneficial effects of CB-1 agonists with spatial and temporal specificity of the endocannabinoid system unlike that achieved with exocannibinoids.